Tag Archives: stocks

3 Biotech Stocks Buoyed By Potential Blockbuster Drugs

Sentiment on biotech stocks overall ebbs and flows, but biotech companies can carve very individual paths. Drug company investors look to product pipelines to spot potential growth, especially for scientifically novel assets that can stand out from the pack. These three biotech stocks have outperformed the group in the past few months thanks to potential blockbuster drugs. • Juno Therapeutics ( JUNO ) is up 68% since its early February all-time low — which was also the IBD Medical-Biomed/Biotech group’s nearly two-year low point — as investors have regained confidence in its cancer-fighting pipeline. Juno is working in the cutting-edge field of cell therapy, in which patients’ own cells are re-engineered to help their immune systems kill cancer cells, in this case the chimeric antigen receptor (CAR) T cells. Juno’s leading candidate, JCAR015, is in midstage testing for acute lymphoblastic leukemia, for which it showed stunning success rates in earlier trials. Last month, its partner Celgene ( CELG ) said it would exercise its option to commercialize JCAR015 and two similar candidates outside of North America and China, under a 10-year, $1 billion partnership that the two companies inked last summer. Also last month, Juno showed off some of its earlier-stage CAR-T candidates at the annual meeting of the American Association for Cancer Research, targeting different receptors in other types of blood cancer. When the abstracts for the meeting were released in March, Leerink analyst Michael Schmidt wrote that Juno’s stock should be supported by “clinical data readouts supporting Juno’s business strategy to develop differentiated, potentially best-in-class CAR-T products that could generate translational insights in hematologic and solid tumor indications.” • BioMarin Pharmaceutical ( BMRN ) is up 29% since its early February 20-month low as it recovered from the FDA’s rejection of its muscular-dystrophy drug Kyndrisa in January. At its R&D day last month, BioMarin rolled out strong early data for two pipeline candidates, one for hemophilia and one for achondroplasia, a form of dwarfism. The hemophilia data brought particular attention, as it was the first-ever evidence on gene therapy for the disease in humans. After the therapy, BMN 270, was delivered once to eight patients, all of their conditions went from severe to mild-to-moderate. This was far better than expected. In a video recorded for clients a couple of weeks later, Evercore ISI analyst John Scotti described the mood at BioMarin’s event: “When they started presenting (the data), jaws just went to the floor. There was an audible gasp in the room.” The market for hemophilia A, the most common type, runs at $4 billion a year. Analysts say a successful gene therapy could massively disrupt the market of clotting factors that have to be infused weekly at least. • Intercept Pharmaceuticals ( ICPT ) is up 52% from its 28-month low in February, after its lead drug Ocaliva passed a major hurdle to market last month. An FDA advisory committee voted to grant it accelerated approval for a liver condition called primary biliary cholangitis (PBC), which the agency has until May 29 to decide on. While the PBC market is expected to bring in a healthy revenue stream for Intercept, the potential blockbuster indication is in nonalcoholic steatohepatitis (NASH), a liver-scarring disease that affects millions of Americans but has no treatment. Intercept is conducting a large phase-three trial of Ocaliva in the disease, with a launch not expected for several years. But the FDA panel vote did imply that the experts see the benefits as outweighing the drug’s known safety issues. Ocaliva’s potential has driven buyout speculation around Intercept stock, which has also helped to push up shares. A particular burst of this came on Feb. 12 when anonymous sources suggested that the company was exploring a sale, though nothing’s yet come of it.

CyberArk Yanked On Imperva ‘Quota’ Blunder, Lagging FireEye Sales

Cybersecurity stocks toppled broadly Friday despite a  CyberArk Software ( CYBR ) blowout Q1, losing ground on disappointing results from FireEye ( FEYE ) and Imperva ( IMPV ) that included, respectively, a sudden CEO shift and ousted EMEA management on lagging sales. IBD’s 26-company Computer Software-Security industry group, which already ranks a lowly No. 178 of 197 groups tracked, was down 5.5% in morning trading on the stock market today , touching a more than two-month low. Imperva and FireEye stocks led the deluge, down a respective 26% and 18%, near 33.50 and 13. CyberArk stock was down 2%, near 39.50. In fact, the only stocks on the rise in the sector were tiny Mimecast ( MIME ) and Qualys ( QLYS ), which was up just a fraction. Viewfinity ‘Meaningfully’ Helps CyberArk Late Thursday, CyberArk reported 43% year-over-year sales growth to $46.9 million and 23 cents earnings per share, up 44% vs. the year-earlier quarter. Both metrics topped the consensus of 17 analysts polled by Thomson Reuters for $43.4 million and 16 cents. Current-quarter guidance for $47.5 million to $48.5 million in sales and 18-20 cents EPS ex items beat Wall Street’s forecast for $47.5 million and 18 cents at the midpoints. On a year-over-year basis, sales would be up 32%, and EPS minus items would be flat. License sales drove CyberArk’s Q1, up 38% to $27.5 million (59% of total revenue), leading 41% growth in the maintenance and professional services segment. Q1 marked acquisition Viewfinity’s first “meaningful contribution,” Piper Jaffray analyst Andrew Nowinski wrote in a research report. Nowinski reiterated an overweight rating and 55 price target on CyberArk stock, noting “broad adoption” across all segments. “They are seeing increased activity with midsize organizations, including universities, credit unions and law firms, which supports the belief that firms of all sizes need this layer of security,” he wrote. Government growth included six-figure deals in all three regions. FireEye Sees ‘Inflection Point’ Dougherty analyst Catharine Trebnick called FireEye’s Q1 an “inflection point” that saw subscriptions replace products as FireEye’s leading segment — up 71% vs. down 16% on a year-over-year basis. The unexpected transition caused FireEye’s Q1 sales to miss but billings to fly. And CEO David DeWalt stepped down to executive board chairman, succeeded by Kevin Mandia, Mandiant founder. FireEye acquired Mandiant in 2014, and Mandia has held several positions at FireEye since. Late Thursday, FireEye reported $168 million in sales and $186 million in billings minus items, up a respective 34% and 23%. A 47-cent loss per-share ex items shrunk by a penny vs. last year’s loss. Billings topped FireEye’s $163 million-$183 million model, and losses beat the consensus of 35 analysts polled by Thomson Reuters for 50 cents. But sales missed the projection for $171.8 million, and on Friday, at least four analysts cut their price targets on FireEye stock. Of the 28 deals worth more than $1 million, 80% included multiple products/subscriptions, and 50% had three or more, Trebnick wrote in a report. More than half of the seven-figure deals included FireEye-as-a-Service — or cloud — products. Trebnick is neutral on FireEye stock. For the current quarter, FireEye guided to $178 million to $185 million in sales, up 23% at the midpoint, and a 38-cent to 40-cent per-share loss minus items, missing the consensus for $192.8 million and a 36-cent loss. Billings views for $200 million to $215 million would be up 16%. Imperva’s ‘Doubly Whammy’ Hits Q1 Imperva, on the other hand, experienced a “double whammy” during Q1 as Web-application firewall and Europe/Middle East/Asia sales stalled, prompting the firm to shift channel priorities and remove its EMEA head of sales. Summit Research analyst Srini Nandury reiterated a buy rating but trimmed his price target on Imperva stock to 50 from 70. Imperva trimmed Q2 guidance but inched 2016 views up — the latter of which Nandury sees as an impossibility. “We worry that the year will be back-end-loaded with no margin of error,” he wrote in a report. For Q1, Imperva reported $59.8 million in sales, up 34%, and a 25-cent per-share loss minus items vs. a 26-cent loss in the year-earlier quarter. Sales met Wall Street expectations, while losses were better by 3 cents. Imperva’s Q2 view for $65.5 million to $66.5 million in sales would be up 23%, but it missed the consensus of 22 analysts polled by Thomson Reuters for $70.2 million. The company’s outlook for a 2-cent to 4-cent loss per share ex items edged views for a 4-cent loss. “Guidance was lowered mainly due to sales execution challenges in EMEA and U.S.,” Nandury wrote in a report. “Some sales force reps were only selling Database Security product so that they can close out their quota for the quarter, while ignoring lower-priced WAF products.” But Nandury sees the issues as fixable. Gartner, IDC and Forrester industry trackers rate Imperva’s products highly, he wrote. Amazon.com ‘s ( AMZN ) Amazon Web Services cloud business can’t touch Imperva’s Database Security, he said. “We do not see evidence that enterprises are going to rely on cloud providers such as AWS to provide security to their data,” he wrote.

Declining Housing Starts Equals Big Profits

Since peaking at 2,111 on April 20, 2016, the S&P 500 has rolled over. The broad market index now sits at 2,050 – nearly 3% lower in just a couple of weeks. The S&P 500 chart below has a distinctly negative look to it. Click to enlarge As the S&P 500 peaked, the moving average convergence divergence (MACD) momentum indicator showed significant negative divergence. This is a strong warning sign that the current rally is exhibiting exhaustion and could be vulnerable to a reversal. The S&P is well-below its 9-day exponential moving average (EMA) of 2,068, which means the market could test its 50-day moving average at 2,035. But given recent negative readings on a host of economic reports here and around the globe, there’s a real possibility that a much deeper move is in the cards. And should the market pass through the 2,035 level, there is no real support until roughly 1,980. That’s another 3.4% from current levels. For this reason, traders should use any strength in the market to unload long positions, while also adding short positions. One possible short position is the S&P Homebuilders Fund (NYSE: XHB ) You see, the homebuilding sector is vulnerable here to a sharp pullback. Below is a chart of XHB… Click to enlarge This chart looks eerily similar to the S&P 500 chart. It shows that XHB has also fallen below its 9-day EMA, while also sitting at its 50-day moving average. This means the $34 level effectively becomes XHB’s new level of resistance. This provides an excellent opportunity to short XHB. With the close proximity to the new resistance level at $34, we can quickly exit the position if resistance with a small loss if resistance breaks. On the other hand, if the nine-day resistance holds, XHB should fall to one of the lower support lines at about $31.20 or as low as $30.20. Now, we hold that the $30.20 price target best aligns with our expectation of a moderate pullback (~3.4%) in the S&P 500. This make $30.20 a reasonable target over the next few weeks. XHB closed at $33.29 today. Now, by taking a short position at this level, we’re risking $0.54 per share if the stock moves higher. Conversely, we stand to pocket $3.00 per share if we’re right and XHB moves lower. That gives us a good risk/reward setup. But we can mitigate our risk even further by purchasing put options on XHB instead of shorting the stock. Here’s how… Let’s assume you’d typically short 500 shares of a recommended stock. At today’s price of $33.29, you’d pony up about $16,650 to short the shares. Now, most investors are willing to absorb a 10% drawdown on shorted stocks should the stock run the wrong direction. This would limit your loss to $1,665 before you exited the position. But, because $1,665 is the most you’re willing to risk, you could instead use the $1,650 to buy the puts. But let’s reduce our risk even further by cutting our maximum loss in half… The XHB June $34 puts closed Thursday at $1.15. With $825, you can purchase seven put options on XHB. Since each option contract covers 100 shares, that gives you control of 700 shares of XHB – versus the 500 shares you would have shorted with the $16,665. You’ve reduced the risk on this trade, while also increasing the potential reward by controlling more shares. This is the right way to speculate with puts. Of course, if we’re wrong on this trade, you could lose 100% of the money you used to buy the puts. But it’s far better to lose 100% of $825 than to lose 10% of $16,665. And if we’re right on this trade, you can make more money by owning seven puts than by shorting 500 shares. So, by purchasing puts instead of shorting the shares, we reduce our risk and increase our potential reward. It makes for a more intelligent trade for managing risk/reward. Here’s the trade in a nutshell… Buy the XHB June $34 put options (XHB160610P0003400) up to $1.25. This option closed yesterday at $1.15 when XHB closed around $33.29 per share. You should be able to get into this trade as long as XHB is trading above $33.30 per share by the time you enter your order. If the stock falls and the option moves out of range, or if the option spikes higher as a result of this recommendation, give the trade a day or two to come back into range. Going forward, if XHB falls to our downside target at $30.20 per share, the June $34 puts will be worth at least $3. That’s a 161% gain on the trade. Once the options have double in price, sell half the position. This will eliminate any chance of a losing trade. Then focus on maximizing profits if XHB moves lower. One caveat…. It’s important to remember this is a speculative trade. We’re buying short-term options in anticipation of a stock market pullback. There’s no guarantee the market will fall or that XHB will decline even if the broader market falls. You can lose everything you put into this trade. So, please, limit your risk to less than half of what you would normally be willing to lose on the stock. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.